清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

医学 Evolocumab公司 血管病学 内科学 2型糖尿病 脂肪组织 糖尿病 心脏病学 2型糖尿病 还原(数学) 脂蛋白 胆固醇 内分泌学 载脂蛋白A1 数学 几何学
作者
Meng-Meng Yu,Xin Zhao,Yinyin Chen,Xinwei Tao,Junbo Ge,Hang Jin,Meng-Su Zeng
出处
期刊:Cardiovascular Diabetology [BioMed Central]
卷期号:22 (1) 被引量:1
标识
DOI:10.1186/s12933-023-01857-w
摘要

Abstract Background Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary inflammation revealed by this novel index could be alleviated after evolocumab treatment in T2DM remains unknown. Methods From January 2020 to December 2022, consecutive T2DM patients with low-density lipoprotein cholesterol ≥ 70 mg/dL on maximally tolerated statin and taking evolocumab were prospectively included. In addition, patients with T2DM who were taking statin alone were recruited as control group. The eligible patients underwent baseline and follow-up coronary CT angiography with an interval of 48-week. To render patients with evolocumab as comparable to those controls, a propensity-score matching design was used to select the matched pairs with a 1:1 ratio. Obstructive lesion was defined as the extent of coronary artery stenosis ≥ 50%; the numbers inside the brackets were interquartile ranges. Results A total of 170 T2DM patients with stable chest pain were included [(mean age 64 ± 10.6 [range 40–85] years; 131 men). Among those patients, 85 were in evolocumab group and 85 were in control group. During follow-up, low-density lipoprotein cholesterol (LDL-C) level (2.02 [1.26, 2.78] vs. 3.34 [2.53, 4.14], p < 0.001), and lipoprotein(a) (12.1 [5.6, 21.8] vs. 18.9 [13.2, 27.2], p = 0.002) were reduced after evolocumab treatment. The prevalence of obstructive lesions and high-risk plaque features were significantly decreased ( p < 0.05 for all). Furthermore, the calcified plaque volume were significantly increased (188.3 [115.7, 361.0] vs. 129.3 [59.5, 238.3], p = 0.015), while the noncalcified plaque volume and necrotic volume were diminished (107.5 [40.6, 180.6] vs. 125.0 [65.3, 269.7], p = 0.038; 0 [0, 4.7] vs. 0 [0, 13.4], p < 0.001, respectively). In addition, PCAT density of right coronary artery was significantly attenuated in evolocumab group (− 85.0 [− 89.0, − 82.0] vs. − 79.0 [− 83.5, − 74.0], p < 0.001). The change in the calcified plaque volume inversely correlated with achieved LDL-C level (r = − 0.31, p < 0.001) and lipoprotein(a) level (r = − 0.33, p < 0.001). Both the changes of noncalcified plaque volume and necrotic volume were positively correlated with achieved LDL-C level and Lp(a) ( p < 0.001 for all). However, the change of PCAT RCA density only positively correlated with achieved lipoprotein(a) level (r = 0.51, p < 0.001). Causal mediation analysis revealed Lp(a) level mediated 69.8% ( p < 0.001) for the relationship between evolocumab and changes of PCAT RCA . Conclusions In patients with T2DM, evolocumab is an effective therapy to decrease noncalcified plaque volume necrotic volume, and increase calcified plaque volume. Furthermore, evolocumab could attenuate PCAT density, at least in part, via the reduction of lipoprotein(a).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武的碧玉完成签到,获得积分10
8秒前
8秒前
科研通AI6.4的应助被LeoYiS214采纳,获得30
21秒前
keyan123完成签到,获得积分10
22秒前
愉快的书桃完成签到,获得积分10
26秒前
31秒前
在水一方的应助被张张张采纳,获得10
31秒前
00hello00发布了新的文献求助10
34秒前
00hello00发布了新的文献求助10
34秒前
体贴怡完成签到,获得积分10
36秒前
44秒前
Dino完成签到 ,获得积分10
46秒前
LeoYiS214发布了新的文献求助30
46秒前
耍酷的手套完成签到,获得积分10
46秒前
Gilgardea发布了新的文献求助10
51秒前
科研狗的春天完成签到 ,获得积分10
55秒前
虚心的紫夏完成签到,获得积分10
1分钟前
传奇3的应助被LeoYiS214采纳,获得30
1分钟前
1分钟前
张张张发布了新的文献求助10
1分钟前
洁净寡妇完成签到,获得积分10
1分钟前
1分钟前
LeoYiS214发布了新的文献求助30
1分钟前
敏感天曼完成签到,获得积分10
1分钟前
张张张完成签到,获得积分10
1分钟前
呆萌的孤云完成签到,获得积分10
1分钟前
ChenYQ完成签到,获得积分10
1分钟前
果酱完成签到,获得积分10
2分钟前
从容煜城完成签到,获得积分10
2分钟前
仁爱的鞋子完成签到,获得积分10
2分钟前
木头鱼完成签到,获得积分10
2分钟前
单身的曲奇完成签到,获得积分10
2分钟前
李健的小迷弟的应助被shiqiyuan采纳,获得10
2分钟前
诚心金渐基完成签到 ,获得积分10
2分钟前
壮观幻波完成签到,获得积分10
2分钟前
清爽小凡完成签到,获得积分10
3分钟前
ClaraReed673发布了新的文献求助10
3分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分10
3分钟前
懦弱的绿蝶完成签到,获得积分10
3分钟前
CodeCraft的应助被zhangzhangzhang采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166364
求助须知:如何正确求助?哪些是违规求助? 9559484
关于积分的说明 21750435
捐赠科研通 7757158
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553488
邀请新用户注册赠送积分活动 2473812